Literature DB >> 9425739

Systemic antigen in the treatment of T-cell-mediated autoimmune diseases.

R Liblau1, R Tisch, N Bercovici, H O McDevitt.   

Abstract

Systemic injection of antigen is one of the approaches that reproducibly induces effective antigen-specific hyporesponsiveness. Here, Roland Liblau and colleagues discuss the cellular and molecular bases of such tolerance, review the current use of this therapeutic strategy in experimental organ-specific autoimmune diseases and analyse what steps are necessary to make this approach suitable for clinical use.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9425739     DOI: 10.1016/s0167-5699(97)01171-7

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  17 in total

1.  Single dose intranasal administration of retinal autoantigen generates a rapid accumulation and cell activation in draining lymph node and spleen: implications for tolerance therapy.

Authors:  A D Dick; V Sharma; J Liversidge
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

2.  Specific immunotherapy of experimental myasthenia gravis by a novel mechanism.

Authors:  Jie Luo; Alexander Kuryatov; Jon M Lindstrom
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

3.  Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen.

Authors:  Amy D Higgins; Marianne A Mihalyo; Adam J Adler
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

4.  Multimerized T cell epitopes protect from experimental autoimmune diabetes by inducing dominant tolerance.

Authors:  Eliane Piaggio; Lennart T Mars; Cécile Cassan; Julie Cabarrocas; Maria Hofstätter; Sabine Desbois; Emilie Bergereau; Olaf Rötzschke; Kirsten Falk; Roland S Liblau
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-16       Impact factor: 11.205

5.  Evaluating candidate autoantigens in rheumatoid arthritis.

Authors:  A P Cope; G Sønderstrup
Journal:  Springer Semin Immunopathol       Date:  1998

Review 6.  The use of mouse models to better understand mechanisms of autoimmunity and tolerance.

Authors:  Fumi Miyagawa; Jan Gutermuth; Hong Zhang; Stephen I Katz
Journal:  J Autoimmun       Date:  2010-07-23       Impact factor: 7.094

7.  Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains.

Authors:  Jon Lindstrom; Jie Luo; Alexander Kuryatov
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

8.  Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide.

Authors:  Nathan R Martinez; Petra Augstein; Antonis K Moustakas; George K Papadopoulos; Silvia Gregori; Luciano Adorini; David C Jackson; Leonard C Harrison
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 9.  Vaccine against autoimmune disease: antigen-specific immunotherapy.

Authors:  Robert P Anderson; Bana Jabri
Journal:  Curr Opin Immunol       Date:  2013-03-13       Impact factor: 7.486

10.  Blood-borne soluble protein antigen intensifies T cell activation in autoimmune CNS lesions and exacerbates clinical disease.

Authors:  F Odoardi; N Kawakami; W E F Klinkert; H Wekerle; A Flügel
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.